New evidence supporting the efficacy and safety of venetoclax in elderly patients with relapsed, refractory chronic lymphocytic leukaemia (CLL) is encouraging and may inform prescribing choices in this patient group who otherwise may have few clear therapeutic options, researchers suggest. The team from the UK and US looked at key safety measures and efficacy in ...
Evidence ‘encouraging’ for venetoclax in elderly with relapsed, refractory CLL
By Jennie James
14 Nov 2019